PMID- 16211545
OWN - NLM
STAT- MEDLINE
DCOM- 20060110
LR  - 20171116
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 104
IP  - 10
DP  - 2005 Nov 15
TI  - Zeta-chain associated protein 70 and CD38 combined predict the time to first 
      treatment in patients with chronic lymphocytic leukemia.
PG  - 2124-32
AB  - BACKGROUND: Zeta-chain associated protein (ZAP)-70 has been proposed as a 
      surrogate marker for immunoglobulin heavy-chain variable region (IgVH) mutation 
      in chronic lymphocytic leukemia (CLL), but it is still not clear whether it is an 
      independent prognostic factor. METHODS: The authors evaluated ZAP-70 expression 
      by flow cytometry in 201 untreated patients and correlated ZAP-70 levels with 
      CD38 expression, genetic abnormalities detected by fluorescence in situ 
      hybridization (FISH), and the time from diagnosis to first treatment. RESULTS: 
      Fifty-seven patients (28%) were positive for ZAP-70 (> or = 20%). Positive ZAP-70 
      status was associated with advanced disease stage, atypical morphology, 
      CD38-positive status, trisomy 12, del(6q), or no detectable abnormalities; 
      negative ZAP-70 status was correlated with del(13q) as a sole abnormality. The 
      treatment-free interval (TFI) was 17.7 months for ZAP-70-positive patients and 
      44.6 months for ZAP-70-negative patients (P < 0.001). Multivariate analysis in 
      117 patients identified advanced stage, CD38 > or = 7%, and the absence of 
      del(13q) as a sole abnormality as independent factors for short TFI. Excluding 
      FISH, ZAP-70 status acquired independent prognostic value along with CD38 status. 
      The authors proposed a risk model that combines ZAP-70 and CD38 to identify 
      patients who are likely to progress. When both markers were positive, the TFI was 
      12 months; when both were negative, the median TFI was 54 months; a median TFI of 
      26 months was observed in patients who had discordant results (P < 0.00001). 
      CONCLUSIONS: The current findings suggested that both ZAP-70 and CD38 should be 
      tested prospectively in all patients with early-stage CLL.
CI  - Copyright 2005 American Cancer Society
FAU - Del Giudice, Ilaria
AU  - Del Giudice I
AD  - Section of Hemato-Oncology, Institute of Cancer Research, Sutton, Surrey, United 
      Kingdom.
FAU - Morilla, Alison
AU  - Morilla A
FAU - Osuji, Nnenna
AU  - Osuji N
FAU - Matutes, Estella
AU  - Matutes E
FAU - Morilla, Ricardo
AU  - Morilla R
FAU - Burford, Anna
AU  - Burford A
FAU - Maravelaki, Sonia
AU  - Maravelaki S
FAU - Owusu-Ankomah, Kwasi
AU  - Owusu-Ankomah K
FAU - Swansbury, John
AU  - Swansbury J
FAU - A'Hern, Roger
AU  - A'Hern R
FAU - Brito-Babapulle, Vasantha
AU  - Brito-Babapulle V
FAU - Catovsky, Daniel
AU  - Catovsky D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.2 (ZAP-70 Protein-Tyrosine Kinase)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/*biosynthesis
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*metabolism/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Risk Factors
MH  - ZAP-70 Protein-Tyrosine Kinase/*biosynthesis
EDAT- 2005/10/08 09:00
MHDA- 2006/01/13 09:00
CRDT- 2005/10/08 09:00
PHST- 2005/10/08 09:00 [pubmed]
PHST- 2006/01/13 09:00 [medline]
PHST- 2005/10/08 09:00 [entrez]
AID - 10.1002/cncr.21437 [doi]
PST - ppublish
SO  - Cancer. 2005 Nov 15;104(10):2124-32. doi: 10.1002/cncr.21437.